Misericordia University

Misericordia Digital Commons
Medical Imaging Senior Posters

Medical Imaging Department

2021

Hypofractionation Treatment of Favorable Intermediate-risk
Prostate Cancer
Carlos Torres-Teran
torrestc@misericordia.edu

Follow this and additional works at: https://digitalcommons.misericordia.edu/medimg_seniorposters
Part of the Medicine and Health Sciences Commons

Recommended Citation
Torres-Teran, Carlos, "Hypofractionation Treatment of Favorable Intermediate-risk Prostate Cancer"
(2021). Medical Imaging Senior Posters. 18.
https://digitalcommons.misericordia.edu/medimg_seniorposters/18

This Poster is brought to you for free and open access by the Medical Imaging Department at Misericordia Digital
Commons. It has been accepted for inclusion in Medical Imaging Senior Posters by an authorized administrator of
Misericordia Digital Commons. For more information, please contact jluksa@misericordia.edu,
mcech@misericordia.edu.

Hypofractionation Treatment of Favorable Intermediate-risk Prostate Cancer
Student Researcher: Carlos Torres-Teran
Faculty Mentor: Loraine Zelna, M.S., R.T. (R) (MR)
Introduction

Patient Demographics & Medical History

This research-based project will demonstrate the efficacy of a moderate
hypofractionated regimen for the treatment of favorable intermediaterisk prostate cancer. Prostate cancer is a major cause of disease and
mortality among men. Research indicates that each year, 1.6 million
men are diagnosed with it and 366,000 die from it. Diagnosis is based
on rectal examination, serum prostate specific antigen (PSA)
measurement, and when essential, transrectal prostate needle biopsy
followed by a Gleason score obtained from it. When treating prostate
cancer, identifying a Gleason score is the deciding factor in choosing
from a wide spectrum of treatment options ranging from supervision to
multimodal treatment. Upon completion of essential tests, the primary
tumor is assigned a stage based on the American Joint Committee on
Cancer’s (AJCC) 8th edition Tumor Node Metastasis (TNM) staging
system for prostate cancer and the patient is placed in a risk group. If
radiation therapy treatment is required, the patient will undergo a
process consisting of a treatment simulation followed by treatment
planning. The preferred External Beam Radiation Therapy (EBRT)
regimen is moderate hypofractionation. This prospect focuses on a case
study of a 54-year-old gentleman who successfully underwent pelvic
radiation therapy using hypofractionation doses for the treatment of
prostate cancer.

• 54-year-old, male patient
• Presented with voiding complaints including frequency of urination
and awakening once per night to void
• Family history of prostate cancer: brother diagnosed at age 61 and
treated with radiation
• PSA levels were monitored
• 03/12/17 2.09 ng/ml PSA
• 04/14/18 2.2 ng/ml PSA
• 04/14/19 2.93 ng/ml PSA
(Delta Medix, 2020)

Prostate Cancer
• Is unregulated, uncontrolled replication of cells in the prostate
(Long, Rollins, & Smith, 2019)
• Is the most diagnosed cancer in men with approximately 1.6 million
incident cases in 2015 (Pernar, Ebot, Wilson, & Mucci, 2018)
• Is the second most common cause of cancer death among men in the
United States (Pernar et al., 2018)
• Is rare among men younger than forty years of age, with incidence
rates increasing after age fifty-five (Pernar et al., 2018)
• Is responsible for the diagnosis of 191,930 men in the United States
in 2020 (Siegel, Miller, & Jemal, 2020)
• Is diagnosed on average at age sixty-six years (Pernar et al., 2018)

Risk Factors
• Men between ages of 75 to 84 years have the highest rate of
mortality (Vane, 2019)
• Men with diagnosed paternal relatives are at two-fold to three-fold
higher risk of being positive (Pernar et al., 2018)
• Men with paternal relatives who died of prostate cancer have twofold higher risk of death compared with men without a family
history (Pernar et al., 2018)
• Modifiable risk factors
• Alcohol use (Vane, 2019)
• Obesity (Vane, 2019)
• Cigarette smoking (Vane, 2019)
• High-fat diet (Vane, 2019)

Patient Treatment Planning
• 06/06/20 4.57 ng/ml PSA
• Abnormal 1.64 ng/ml PSA Velocity increase in 1 year
• 07/16/20 Transrectal ultrasound-guided needle biopsy of prostate
• Gleason score 3+4 = 7, on right lateral base, right lateral mid,
right medial mid, and right medial apex involving 40% to 60% of
invasive adenocarcinoma on prostate
• Perineural invasion present in some biopsy cores
• Gleason score 3+3 = 6, on right lateral apex involving 15% of
invasive adenocarcinoma on prostate; no perineural invasion
• Negative remaining 7/12 biopsy cores
• Patient was diagnosed with favorable intermediate-risk prostate
cancer
• Diagnosed with stage IIB, T1c, N0, M0, Grade group 2, Gleason
score 3+4 = 7, invasive adenocarcinoma on right side of prostate
(refer to figures 1 and 2)
• 08/17/20 Bone scan and CT of abdomen and pelvis
• Negative for tumor metastasis
• 11/30/20 Hypofractionation treatment began
• Total dose prescribed of 7,000 cGy delivered in 28 fractions (250
cGy per fraction)
• 01/12/21 Hypofractionation treatment ended
• Patient reported episodes of mild loose stool at times for 2
weeks, loss of taste, and decrease in appetite
• 01/23/21 0.46 ng/ml PSA
• PSA level below threshold
• 02/11/21 Treatment follow-up
• Patient reported nocturia once per night, hot flashes (from
androgen deprivation therapy); everything else was negative
• 07/25/21 0.49 ng/ml PSA
• PSA level below threshold
• 08/2021 Treatment follow-up
• Patient reported nocturia; hot flashes have subsided
(Delta Medix, 2020)

Tumor

T1: Clinically inapparent tumor that is not palpable
T2: Palpable tumor confined within prostate
T3: Extraprostatic tumor that does not invade/unfixed
T4: Tumor is fixed/invades structures other than seminal vesicles

Node
Metastasis

NX: Regional lymph nodes cannot be assessed
N0: No positive regional nodes
N1: Metastases in regional node(s)

Figure 1

Risk Stratification Workup
Risk
Group

Grade
Group

Gleason
Score

PSA

Low/Very Low

1

≤6

< 10

Intermediate

2

7 (3+4)

(Favorable/Unfavorable)

3

7 (4+3)

4

8

5

9 – 10

High/Very High

•

Diagnosing Prostate Cancer

10 – 20

> 20

Figure 2

Treatment Set-up

Aligns target for treatment
Picture 2

Varian TrueBeam Linear Accelerator
Gantry
• Rotates around patient
Cone-beam CT scanner
• Assesses/verifies patient positioning
Pillow
• For patient’s head
Vac-Lok
• Immobilizes lower extremities
Ring
• Immobilizes upper extremities
Pendant
• Manipulates TrueBeam and table

For patient’s head

Vac-Lok
•

Immobilizes lower extremities

Ring
•

Immobilizes upper extremities

Picture 1

• Treatment setup is simulated by positioning the patient on the flat
couch going into the unit headfirst, holding onto ring
• A Vac-Lok immobilization device that minimizes patient movement is
made simultaneously
• The patient is aligned to the lasers in the room and marked on the skin
with tattoos
• A CT scan will be done to guide the linear accelerator to target the
lesions accurately and spare critical organs as much as possible during
treatment

Picture 3

aa Bladder Picture 3
aa Prostate Gland
aa Seminal Vesicles
aa Rectum
aa Femoral Head + Greater Trochanter
aa Femoral Head + Greater Trochanter

Picture 4

aa Bladder Picture 4
aa Prostate Gland
aa Seminal Vesicles
aa Rectum

•
•
•
•
•

Refer to figure 2
No very high/high-risk group features
Grade group 2 or 3
Gleason score of 7 (3+4) or (4+3)
PSA 10 – 20 ng/mL

(Schaeffer et al., 2021)

Intermediate Risk Group

M0: No distant metastasis
M1: Distant metastasis

CT Scanner
Pillow

• Physical examination by physician
• Digital rectal examination (DRE)
• Serum prostate specific antigen (PSA) measurement
• Threshold should be less than 4.0 ng/dl (Vane, 2019)
• Velocity increases correlate with risk, aggressiveness, and can
indicate presence of prostate cancer (Catalona, 2018)
• Transrectal ultrasound-guided prostate needle biopsy
• Provides information about tumor pathology (Öztürk &
Yıkılmaz, 2018)
• Gleason score
• First and second most common glandular patterns identified
(Öztürk & Yıkılmaz, 2018)
• Important in terms of disease course and treatment planning
(Öztürk & Yıkılmaz, 2018)
• Pathological scores range from 2 to 10

The TNM System

Treatment Simulation
•

Clinical/Pathologic Features:
Intermediate Risk Group

Prostate Cancer Staging

• Does not require treatment of pelvic lymph nodes (eviCore
healthcare, 2021)
• Hypofractionation radiation-therapy strongly recommended
(eviCore healthcare, 2021)
• Two subcategories
• Favorable intermediate
• Unfavorable intermediate
Favorable intermediate
• Grade group 1 or 2
• <50% biopsy cores positive (eg, <6 of 12 cores)
• Prophylactic lymph node radiation and ADT or antiandrogen
therapy is not used routinely
• Reasonable if additional risk assessments suggest aggressive
tumor behavior
• Preferred Hypofractionated dose regiments that have shown
acceptable efficacy and toxicity
• 3 Gray x 20 fractions
• 2.7 Gray x 26 fractions
• 2.5 Gray x 28 fractions
(Schaeffer et al., 2021)

Hypofractionation Radiation Therapy Facts
• Fraction size between 240 centigrays and 340 centigrays (eviCore
healthcare, 2021)
• Regimens of 6000 centigrays in 20 radiation treatment fractions and
7000 centigrays in 28 radiation treatment fractions suggested
(eviCore healthcare, 2021)
• Increases tumor cell killing without causing a corresponding
increase in damage to surrounding healthy tissues (Campos et al.,
2021)
• Reduces overall treatment time, number of hospital trips, and use of
linear accelerator, thus benefitting patients and treatment centers
(Campos et al., 2021)
• Advantageous for radiation therapy treatment centers with limited
resources, long waiting lists, and/or a geographically dispersed
population in which many patients live far from the center (Campos
et al., 2021)
• No overall difference in severe gastrointestinal and genitourinary
toxicity between non-hypofractionated and hypofractionated
regimens (Sujenthiran et al., 2020)

Conclusion
This research-based project was done to demonstrate the efficacy of a
moderate hypofractionated regimen for the treatment of favorable
intermediate-risk prostate cancer. This 54-year-old male patient was
prescribed a total dose of 7,000 centigrays to be delivered in 28
fractions (250 centigrays per fraction). He received a total dose of
7,000 centigrays as prescribed over 43 elapsed days. After completion
of the treatment, he reported episodes of mild loose stool at times for
two weeks, loss of taste, and decrease in appetite. One month later he
reported nocturia once per night and hot flashes. Six months later he
reported nocturia but no more hot flashes. His PSA was 4.57 ng/ml on
06/06/20 prior to the start of treatment. Upon treatment completion, his
PSA was measured to be 0.46 ng/ml on 01/23/21 and 0.49 ng/ml on
07/25/21. The PSA level decreases demonstrate the efficacy of the
hypofractionated regimen for the treatment of favorable intermediaterisk prostate cancer. This regimen shows no overall difference in
severe gastrointestinal and genitourinary toxicity and reduces the
overall treatment time, the number of hospital trips, and use of the
linear accelerator, thus benefitting patients as well as treatment centers.
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